Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-30T20:09:26.807Z Has data issue: false hasContentIssue false
  • English
  • Français

Epidemiology and Impact of Imipenem Resistance in Acinetobacter baumannii

Published online by Cambridge University Press:  02 January 2015

Ebbing Lautenbach ,
Marie Synnestvedt ,
Mark G. Weiner ,
Warren B. Bilker ,
Lien Vo ,
Jeff Schein  and
Myoung Kim
Ebbing Lautenbach*
Affiliation:
Divisions of Infectious Diseases of the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Marie Synnestvedt
Affiliation:
Division of General Internal Medicineof the Department of MedicinePhiladelphia, Pennsylvania Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Mark G. Weiner
Affiliation:
Division of General Internal Medicineof the Department of MedicinePhiladelphia, Pennsylvania Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Warren B. Bilker
Affiliation:
Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Lien Vo
Affiliation:
Ortho-McNeil Janssen Scientific Affairs, Raritan, New Jersey
Jeff Schein
Affiliation:
Ortho-McNeil Janssen Scientific Affairs, Raritan, New Jersey
Myoung Kim
Affiliation:
Ortho-McNeil Janssen Scientific Affairs, Raritan, New Jersey
*
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 825 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Background.

Acinetobacter baumannii is an emerging gram-negative pathogen that can cause healthcare-acquired infections among patients. Treatment is complicated for cases of healthcare-acquired infection with A. baumannii resistant to imipenem.

Objective.

To elucidate the risk factors for imipenem-resistant A. baumannii (IRAB) infection or colonization and to identify the effect of resistance on clinical and economic outcomes.

Methods.

We analyzed data from 2 medical centers of the University of Pennsylvania. Longitudinal trends in the prevalence of IRAB clinical isolates were characterized during the period from 1989 through 2004. For A. baumannii isolates obtained from 2001 through 2006, a case-control study was conducted to investigate the association between prior carbapenem use and IRAB infection or colonization, and a cohort study was performed to identify the effect of IRAB infection or colonization on mortality, length of stay after culture, and hospital cost after culture.

Results.

From 1989 through 2004, the annual prevalence of IRAB isolates ranged from 0% to 21%. During the period from 2001 through 2006, there were 386 unique patients with A. baumannii isolates, and 89 (23.1%) had IRAB isolates. Prior carbapenem use was independently associated with IRAB infection or colonization (adjusted odds ratio, 3.04 [95% confidence interval, 1.07–8.65]). There was a borderline significant association between IRAB infection or colonization and mortality, although this association was limited to isolates recovered from blood samples (adjusted odds ratio, 5.30 [95% confidence interval, 0.81–34.59]). Compared with patients with imipenem-susceptible A. baumannii infection or colonization, patients with IRAB infection or colonization had a longer hospital stay after culture (median, 21 vs 16 days; P = .07) and greater hospital charges after culture (mean, $334,516 vs $276,059; P = .03). After controlling for patient location in an intensive care unit, transfer from another facility, and length of hospital stay before culture, there was no longer an independent association between IRAB infection or colonization and higher cost after culture and length of stay after positive culture result.

Conclusions.

Many A. baumannii isolates exhibit imipenem resistance, which is strongly associated with prior use of carbapenems. Given the high mortality rate associated with A. baumannii infection or colonization, interventions to curb further emergence of cases of IRAB infection and strategies to optimize therapy are needed.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 30 , Issue 12 , December 2009 , pp. 1186 - 1192
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Falagas, ME, Kopterides, P, Siempos, II. Attributable mortality of Acine-tobacter baumannii infection among critically ill patients. Clin Infect Dis 2006;43:389.Google Scholar
2.Fournier, PE, Richet, H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692–699.Google Scholar
3.Ibrahim, EH, Sherman, G, Ward, S, Fraser, VI, Kollef, MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146–155.Google Scholar
4.Kollef, MH. The importance of appropriate initial antibiotic therapy for hospital-acquired infections. Am I Med 2003;115:582–584.CrossRefGoogle ScholarPubMed
5.Paterson, DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006;43(Suppl 2):S43–S48.Google Scholar
6.Gales, AC, Jones, RN, Sader, HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006;12:315–321.Google Scholar
7.McGowan, JE. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med 2006;119(Suppl 1):S29–S36.Google Scholar
8.Harris, AD, Karchmer, TB, Carmeli, Y, Samore, MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001;32:1055–1061.CrossRefGoogle ScholarPubMed
9.Gasink, LB, Fishman, NO, Weiner, MG, Nachamkin, I, Bilker, WB, Lautenbach, E. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 2006;199:e19–e25. Available at: http://www.amjmed.com/article/PIIS0002934305011502/fulltext. Accessed October 15, 2009.Google Scholar
10.Lautenbach, E, Weiner, MG, Nachamkin, I, Bilker, WB, Sheridan, A, Fishman, NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006;27:893–900.Google Scholar
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 18th informational supplement. CLSI document. Wayne, PA: CLSI, 2008:M100-S18.Google Scholar
12.Defez, C, Fabbro-Peray, P, Bouziges, N, et al.Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect 2004;57:209–216.Google Scholar
13.Falagas, ME, Koletsi, PK, Bliziotis, IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006;55:1619–1629.CrossRefGoogle ScholarPubMed
14.MacAdam, H, Zaoutis, TE, Gasink, LB, Bilker, WB, Lautenbach, E. Investigating the association between antibiotic use and antibiotic resistance: impact of different methods of categorizing prior antibiotic use. Int J Antimicrob Agents 2006;28:325–332.Google Scholar
15.Gasink, LB, Zaoutis, TE, Bilker, WB, Lautenbach, E. The categorization of prior antibiotic use: impact on the identification of risk factors for drug resistance in case control studies. Am J Infect Control 2007;35:638–642.Google Scholar
16.Armitage, P. Test for linear trend in proportions and frequencies. Biometrics 1955;11:375–386.Google Scholar
17.Kleinbaum, DG, Kupper, LL, Morgenstern, H. Epidemiologie Research: Principles and Quantitative Methods. New York, New York: Van Nostrand Reinhold; 1982.Google Scholar
18.Mantel, N, Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–748.Google Scholar
19.Hosmer, DO, Lemeshow, SL. Applied Logistic Regression. New York, New York: Wiley and Sons; 1989.Google Scholar
20.Sun, GW, Shook, TL, Kay, GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996;49:907–916.Google Scholar
21.Mickey, RM, Greenland, S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125–137.Google Scholar
22.Garner, JS, Jarvis, WR, Emori, TG, Horau, TC, Hughes, JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128–140.Google Scholar
23.Lee, SO, Kim, NJ, Choi, SH, et al.Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004;48:224–228.Google Scholar
24.del Mar Tomas, M, Cartelle, M, Pertega, S, et al.Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 2005;11:540–546.Google Scholar
25.Falagas, ME, Kopterides, P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006;64:7–15.Google Scholar
26.Husni, RN, Goldstein, LS, Arroliga, AC, et al.Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest 1999;115:1378–1382.Google Scholar
27.Carbonne, A, Naas, T, Blanckaert, K, et al.Investigation of a nosocomial outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a hospital setting. J Hosp Infect 2005;60:14–18.Google Scholar
28.Smith, PW, Bennett, G, Bradley, S, et al.SHEA/APIC guideline: infection prevention and control in the long-term care facility, July 2008. Infect Control Hosp Epidemiol 2008;29:785–814.Google Scholar
29.Lautenbach, E, Fishman, NO, Bilker, WB, et al.Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162:2469–2477.Google Scholar
30.Lautenbach, E, Strom, BL, Bilker, WB, Patel, JB, Edelstein, PH, Fishman, NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001;33:1288–1294.Google Scholar